FDA Accepts Aquestive Therapeutics’ Anaphylm Application for Review

Aquestive Therapeutics announced Thursday, Oct. 15, that the U.S. Food and Drug Administration (FDA) accepted its resubmitted application for Anaphylm for review. Anaphylm is an epinephrine formulation delivered as a sublingual film. It is designed for emergency treatment of severe allergic reactions. Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.